A survey of recent papers on the subject reveals that only 25–30% of HER-2/neu—positive breast cancer patients responded to trastuzumab [3,6], only ~54% of non-Hodgkin lymphoma patients responded to rituximab [4], and only 28% of metastatic colon cancer patients responded to cetuximab [60]. This evidence concerns the gene ERBB2 and non-Hodgkin lymphoma.